The vaccine candidate-for now just called BNT162b1-"elicited a robust immune response in participants, which increased with dose level and with a second dose", according to a news release from the journal Nature, which published the trial data on August 12.
This week, Russian Federation approved a vaccine even before it started the last phase of clinical trials.
Never before has a vaccine progressed so quickly on so many different fronts, and never before has there been such a short-term impetus to develop, produce, and distribute medical products. If successful, Novavax's candidate will be available to all 92 countries, while AstraZeneca's candidate vaccine will be available to 57 Gavi-eligible countries.
"We are honored to partner with the United Kingdom government to deliver a vaccine that could provide vital protection in the fight against the global health crisis", Stanley C. Erck, president and chief Executive Officer of Novavax said in a statement.
The next phase of Janssen's clinical trials is expected to begin later this year, according to the government.
The latest agreements brings the UK's total number of doses secured to 362 million for a population of 66 million, Reuters said.
As Johnson & Johnson, Sanofi and GlaxoSmithKline move ahead in advanced COVID-19 vaccine supply negotiations with the European Union, AstraZeneca has signed into the union's first finalized agreement.
Canon allegedly hit by Maze ransomware, 10TB data stolen
During this process, Maze will steal unencrypted files from servers and backups and upload them to the threat actor's servers. In a statement to BleepingComputer , a spokesperson for Canon said that they are "currently investigating the situation".
The developing world- which often lacks both a pharmaceutical industry to develop, test, and produce vaccines and the money to purchase them from elsewhere- has been forced to seek supplies from allies or from global groups attempting to obtain vaccines for poor countries.
"We are on track to deliver hundreds of millions of doses by January 2021", he added.
Kate Bingham, chair of the government's vaccines task force, said: "The sooner we start the two-dose study of the Janssen vaccine the sooner we will know whether the vaccine can provide durable, long term protection against COVID-19 infection". The institute plans to submit documents for approval to the health ministry as early as April next year and claims to be capable of producing 30 million doses a year.
The vaccine uses a technology known as recombinant nanoparticle to produce antigens - molecules that are created to spur the immune system into action.
Samples of the vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology.
Doctors or clinics that administer them will have to be paid but these costs should mostly be covered by private and public insurers.